{"count": 1, "results": [{"_id": "25218337", "pmid": 25218337, "title": "Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.", "journal": "Eur J Cancer", "authors": ["Kim ST", "Kang JH", "Lee J", "Park SH", "Park JO", "Park YS", "Lim HY", "Hwang IG", "Lee SC", "Park KW", "Lee HR", "Kang WK"], "date": "2014-11-01T00:00:00Z", "doi": "10.1016/j.ejca.2014.08.005", "meta_date_publication": "2014 Nov", "meta_volume": "50", "meta_issue": "16", "meta_pages": "2822-30", "score": 50060.184, "text_hl": "CONCLUSIONS: Addition of 40 mg @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ to @<m>DISEASE_Xeroderma_Pigmentosum</m> @DISEASE_MESH:D014983 @@@XP@@@ does not increase PFS in our trial, although it does not increase @DISEASE_Drug_Related_Side_Effects_and_Adverse_Reactions @DISEASE_MESH:D064420 @@@toxicity@@@. ", "citations": {"NLM": "Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KW, Lee HR, Kang WK. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014 Nov;50(16):2822-30. PMID: 25218337", "BibTeX": "@article{25218337, title={Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.}, author={Kim ST and Kang JH and Lee J and Park SH and Park JO and Park YS and Lim HY and Hwang IG and Lee SC and Park KW and Lee HR and Kang WK}, journal={Eur J Cancer}, volume={50}, number={16}, pages={2822-30}}"}}]}